Comparative efficacy of inhaled corticosteroids and leukotriene modifiers depending on ASP299GLY-TLR-4 polymorphism in patients with bronchial asthma in the population of AR Crimea.

Авторы

  • Yu. A. Bisyuk
  • A. I. Kurchenko
  • A. I. Dubovyi
  • V. E. Kondratiuk

DOI:

https://doi.org/10.26641/2307-0404.2015.3.53691

Ключевые слова:

asthma, endotoxin, Asp299Gly-TLR-4 polymorphism, fluticasone propionate, montelukast

Аннотация

The study included 39 patients with bronchial asthma. All patients at baseline were stratified into two groups with the genotype AA and AG of polymorphism Asp299Gly TLR-4. The study consisted of 2 periods: a 2-weeks’ run-in period when all patients received low-dose (125 mg) of fluticasone propionate once a day; 24-weeks’ treatment period when patients received fluticasone propionate oncea day or 1 tablet (10 mg) of montelukast per day depending on randomization subgroups. The study results showed that taking of fluticasone propionate by patients with AA genotype TLR-4 for 24 weeks is more effective than montelukast taking; this is evi­denced by a significant increase of FEV1 and improvement of indices of asthma control level (ACL) and quality of life of patients (AQLQ (S)). In patients with AG genotype clinical efficacy of montelukast is superior to fluticasone propionate.

Биографии авторов

Yu. A. Bisyuk

Bogomolets National Medical University
T. Shevchenko boul., 13, Kiev, 01601, Ukraine

A. I. Kurchenko

Bogomolets National Medical University
T. Shevchenko boul., 13, Kiev, 01601, Ukraine

A. I. Dubovyi

SE «Crimean State Medical University named after S.I. Georgievskiy»

V. E. Kondratiuk

Bogomolets National Medical University
T. Shevchenko boul., 13, Kiev, 01601, Ukraine

Библиографические ссылки

Kryuchko TA, Vovk YuA, Tkachenko OYa. [The role of genetic factors in the development of tyazheloy atopicheskoy bronhialnoy asthma in children]. Zhurnal “Zdorov'e Rebenka”. 2012;5(40):58–62. Russian. 2. [MOH Ukraine of 19.03.2007 № 128. "On ap¬pro-val of clinical protocols of medical care in the specialty" Pulmonology "]. K. 2007;146. Ukrainian. 3. Chen S. Association between the TLR4 +896A>G (Asp299Gly) Polymorphism and Asthma: A Systematic Re¬view and Meta-Analysis. J Asthma. 2012;49(10):999–1003. 4. MacRedmond RE, Greene CM, Dorscheid DR. Epithelial expression of tlr4 is modulated in copd and by steroids, salmeterol and cigarette smoke. Respiratory re-search. 2007;8(1):84. 5. Celedón JC, Milton DK, Ramsey CD. Exposure to dust mite allergen and endotoxin in early life and asthma and atopy in childhood. Journal of allergy and cli¬nical immunology. 2007;120(1):144-49. 6. Hankinson JL, Odencrantz JR, Fedan KB. Spiro-metric reference values from a sample of the general us population. American journal of respiratory and critical care medicine. 1999;159(1):179–87. 7. Moore WC, Meyers DA, Wenzel SE. Identifi-cation of asthma phenotypes using cluster analysis in the severe asthma research program. American journal of res¬piratory and critical care medicine. 2010;181(4):315–23. 8. Juniper EF, Bousquet J, Abetz L. Identifying “well-controlled” and “not well-controlled” asthma using the asthma control questionnaire. Respiratory medicine. 2006;100(4):616–21. 9. Kim Y-M, Kim Y-S, Jeon SG, Kim Y-K. Immuno-pathogenesis of allergic asthma: more than the Th2 hypothesis. Allergy, Asthma & Immunology Research. 2013;5(4):189-96. 10. Lundberg A, Wikberg LA, Ilonen J. Lipopoly-saccharide-induced immune responses in relation to the TLR4 (Asp299Gly) gene polymorphism. Clin Vaccine Immunol. 2008;15(12):1878–83. 11. Chang YT, Tseng CC, Lin MC. Mechanism of leukotriene antagonist to attenuate in vitro lipid a induced acute lung injury (ali). Am J Respir Crit Care Med. 2011;183:A2906. 12. Scaparrotta A, Di Pillo S, Attanasi M. Monte-lukast versus inhaled corticosteroids in the management of pediatric mild persistent asthma. Multidiscip Respir Med. 2012;7(1):13. 13. Bousquet J, Menten J, Tozzi CA, Polos PG. Oral montelukast sodium versus inhaled fluticasone propionate in adults with mild persistent asthma. Journal of applied research in clinical and experimental therapeutics. 2005;5(3):402. 14. Miller MR, Hankinson J, Brusasco V. Standardi-sation of spirometry. Eur respir J. 2005;26(2):319–38. 15. Zaborowski T, Wojas-Krawczyk K, Krawczyk P. The effect of CD14 and TLR4 gene polymorphisms on the occurrence of atopic and non-atopic asthma. Adv Clin Exp Med. 2011;20(4): 413-21. 16. Long H, O’Connor BP, Zemans RL. The toll-like receptor 4 polymorphism asp299gly but not thr399ile influences tlr4 signaling and function. PloS one. 2014;9(4):93550. 17. Yang IA, Barton SJ, Rorke S. Toll-like receptor 4 polymorphism and severity of atopy in asthmatics. Genes Immun 2004;5(1):41–45. 18. Juniper EF, Buist AS, Cox FM. Validation of a standardized version of the asthma quality of life ques-tionnaire. CHEST Journal. 1999;115(5):1265–70.

Загрузки

Опубликован

2015-09-23

Как цитировать

1.
Bisyuk YA, Kurchenko AI, Dubovyi AI, Kondratiuk VE. Comparative efficacy of inhaled corticosteroids and leukotriene modifiers depending on ASP299GLY-TLR-4 polymorphism in patients with bronchial asthma in the population of AR Crimea. Med. perspekt. [Интернет]. 23 сентябрь 2015 г. [цитируется по 28 ноябрь 2024 г.];20(3):85-94. доступно на: https://journals.uran.ua/index.php/2307-0404/article/view/53691

Выпуск

Раздел

CLINICAL MEDICINE